Background. Naturally occurring variants of human papillomavirus (HPV) 58 have been defined as lineages and sublineages but little is known about the impact of this diversity on protein function. We investigated the impact of variation within the major (L1) and minor (L2) capsid proteins of HPV58 on susceptibility to neutralizing antibodies.
Human papillomavirus (HPV) is the causative agent of cervical and other anogenital and head and neck cancers and accounts for >600 000 cancer cases globally per annum [1, 2] . Host cell polymerases facilitate replication of the small dsDNA genome, resulting in a typically low evolutionary rate [3] . Despite this low evolutionary rate, distinct genotypes and intragenotype variant lineages have arisen over time [4, 5] . About a dozen or so genotypes from the Alpha-papillomavirus genus are associated with the development of cervical cancer [2] , although the contribution of each genotype is different, with HPV16 and HPV18 alone accounting for approximately 70% of cervical cancer cases [6] .
HPV58 (related to HPV16 within the Alpha-9 species group) accounts for approximately 2%-4% of cervical cancer cases worldwide [6] , but can exhibit large inter-and intraregional variation [7] . Given the magnitude of global cancer cases attributable to HPV, genotypes with relatively low individual prevalence, such as HPV58, contribute significant global HPVassociated morbidity and mortality. Whole-genome sequence analysis of HPV58 strains has led to the delineation of distinct variant lineages (A, B, C, and D) and sublineages (A1, A2, A3, B1, B2, D1, and D2) [8] , which exhibit some geographical bias in their distribution ( Figure 1A ) [9] . Sublineage A2 is the most common variant worldwide, with sublineages A1 and A3 being more common in Asia, and although lineage C accounts for only approximately 9% of sequences overall it accounts for approximately 40% of those in Africa and approximately 2% of those in Asia. Sublineage variants A1 and A3 appear to be overrepresented in high-grade cervical disease compared to lineage C [10] . As these observations have been made on relatively few sequences, further work will be required to fully appreciate the HPV58 variant attribution to risk of cervical disease globally.
The HPV capsid consist of 360 copies of the major capsid protein, L1, arranged into 72 pentamers forming a T = 7 icosahedral lattice [11] . Distribution of the minor capsid protein, L2, may be asymmetrical and/or stochastic with an upper estimate of 1 molecule per L1 pentamer [12, 13] . The L1 protein facilitates virus attachment to host cells, whilst the L2 protein is essential for subsequent virus infectivity. L1 surface-exposed external loops are the target for the majority of type-specific neutralizing antibodies [14, 15] Human papillomavirus 58 (HPV58) L1 and L2 variation. A, Geographical distribution of HPV58 variants [9] . B, Neighbor-joining tree constructed using concatenated L2 and L1 sequences derived from published partial (*) or full-length genome sequences (accession numbers: D90400, EU918765, GQ47285, KU298920, KX514422, FJ407199-FJ407201*, FJ407192*, FJ407194-FJ407195*, FJ385261-FJ385268, HQ537752-HQ537777, KC860269-KC860271, AB819275-AB819279). Sublineage attribution (A1, A2, A3, B1, B2, C, D1, and D2) is based on whole-genome sequences [8] . C, Inter-and intralineage sequence diversity, with residues numbered according to the reference HPV58 sequence (D90400) starting with the second methionine according to convention (https://pave.niaid.nih.gov/). D, Pseudovirus preparations characterized for particle dimension (nm median [interquartile range]), infectivity, L1 concentration, and resulting particle-to-infectivity ratio. Abbreviation: TCID 50 , 50% tissue culture infectious dose.
evidence that neutralizing antibodies are sufficient to confer protection [16, 17] , has led to the development of highly efficacious virus-like particle (VLP)-based prophylactic vaccines [1] . Bivalent and quadrivalent vaccines target the most prevalent  oncogenic genotypes (HPV16 and HPV18), while the nonavalent HPV vaccine targets an additional 5 oncogenic genotypes  (HPV31, HPV33, HPV45, HPV52, and HPV58 ). Both quadrivalent and nonavalent vaccines target HPV6 and HPV11, which are associated with the development of genital warts.
Detectable HPV infection can persist for many months [18] , before being cleared by the host cell-mediated immune response [2] . HPV clearance is defined reasonably as an extended period without same-type detection, but in some cases subsequent redetection of the same genotype is likely to be an unresolved prior infection rather than a new acquisition [19] . Only a subset of individuals seroconvert following incident infection [20] . Serum antibodies tend to be of low titer but persist for many years [20, 21] , and may reduce the risk of new type-specific infections [22] .
The potential biological consequences of HPV lineage and sublineage genome variation are uncertain. Studies examining the potential impact of natural variation on L1 antigenicity have been limited to the examination of HPV16 [23, 24] , HPV31 [25] , HPV33 [26] , and HPV45 [27] , but variant-specific differences in sensitivity to L1 antibodies have been demonstrated. Although these variant residues have been fixed in the evolutionary history of HPV, these data suggest that they may nevertheless influence sensitivity to vaccine-induced or natural immunity.
Here we evaluate the sensitivity of HPV58 lineage and sublineage variants to neutralization by a broad range of HPV58-specific antibodies.
METHODS

Ethics Statement
Serum samples were obtained from women attending the Gynaecology Outpatients Clinic, San Gerardo Hospital, Monza, Italy (ethics committee reference 08/UNIMIB-HPA/HPV1; No. 1191). All animal husbandry and procedures were carried out in strict accordance with United Kingdom Home Office guidelines, were governed by the Animals (Scientific Procedures) Act of 1986, and were performed under licenses for procedures under PPL 70/9025 and 70/9026.
Natural Infection Serum Samples
Serum samples representing a source of natural infection antibodies were obtained from women (n = 201; Gynaecology Outpatients Clinic, San Gerardo Hospital, Monza, Italy) following a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. HPV58 DNA sequencing was performed with primer sets designed for the regions containing a partial long control region (LCR) fragment and a complete E6 and E7 open reading frame [28] .
Murine Monoclonal Antibodies
BALB/c mice (Beijing Vital River Laboratory Animal Technology Co.) were immunized subcutaneously 3 times, 2 weeks apart, with HPV58 VLPs (100 µg/animal) absorbed with aluminum adjuvant [29] . A panel of anti-HPV58 monoclonal antibodies (MAbs) was then generated using standard hybridoma technology and screened using a pseudovirus (PsV)-based neutralization assay. MAbs were produced in mouse ascites and purified by protein A affinity chromatography. The purified MAbs were subsequently diluted to 1.0 mg/mL in phosphate-buffered saline and stored at −20°C.
L1l2 Pseudovirus
Codon-optimized HPV58 L1 and L2 genes representing consensus lineage variant sequences were synthesized (GeneArt; Thermo Fisher Scientific) and additional chimeric constructs were made by standard restriction enzyme digestion and site-directed mutagenesis (QuikChange Site-Directed Mutagenesis Kit, Agilent Technologies). All inserts were confirmed by Sanger sequencing.
Bicistronic psheLL vectors containing these inserts were assembled and together with luciferase reporter (pGL4.51 [luc2/CMV/Neo]; Promega) used to transfect 293TT cells, as previously described [30] , using a protocol developed to reduce the inclusion of excess nonreporter-containing "cold capsids" [31] . PsVs were purified by ultracentrifugation on an iodixanol (Sigma-Aldrich) gradient and particle characteristics determined by electron microscopic analysis, sodium dodecyl sulfate polyacrylamide gel electrophoresis, and infectivity assays [25, 30] . Ten PsV particles were measured from each preparation and the median nm diameter and interquartile range (IQR) estimated. The equivalent of a 50% tissue culture infectious dose (TCID 50 ) was estimated for each PsV preparation using the SpearmanKarber method. The L1 concentration of PsV stocks were determined by semiquantitative western blot using the CamVir-1 antibody (Abcam, UK). Particle-to-infectivity ratios were determined on the basis of an estimated particle amount of 3 × 10 7 particles per ng L1 protein (http://home.ccr.cancer.gov/lco/production.asp), with the ratio normalized for the input volume and the TCID 50 .
Animal Antisera
Sera from New Zealand White rabbits (n = 3) immunized with baculovirus-derived L1 VLP based upon the HPV58 A1 L1 sequence were available from a previous study [32] .
HPV58 A1 and C L1L2 VLP without reporter were generated from 293TT cells as previously described [33] . VLP were adsorbed onto aluminum hydroxide (Alhydrogel; Invivogen) before addition of the monophosphoryl lipid A-based Sigma Adjuvant System (Sigma-Aldrich). BALB/c mice were injected intramuscularly with 2 µg HPV58 A1 or C VLP on day 0 and day 14, before a terminal blood sample was taken at day 21. Pretreatment blood samples were collected prior to the initial immunization.
Neutralization Assay
The PsV neutralization assay [34] was performed as previously described [30] . A standardized input of 300 TCID 50 was used for all PsVs. Antibody samples were subjected to serial dilutions, with the antibody titer (or inhibitory concentration 80% [IC 80 ] for MAbs), resulting from an 80% reduction in the luciferase signal produced by control wells containing PsV and cells only, estimated by interpolation. For analysis purposes, serum samples with titers less than the lower limit of detection (LOD, 50) were assigned a censored value of 25. To demonstrate the reproducibility of the low neutralizing antibody titers typical of natural infection, serum samples (n = 22) were retested (n = 3) against HPV58 A1 PsV, resulting in a median Pearson correlation coefficient of 0.964.
Hpv58 Pentamer Crystal Topography
The crystal structure of the HPV58 A1 L1 pentamer (Protein Data Bank [PDB] code: 5Y9E) was used as template [29] . An HPV58 C L1 homology model was made using SWISS MODEL (https://swissmodel.expasy.org/) [35, 36] . The quality of the predicted model was assessed by their qualitative model energy analysis (QMEAN4) and global model quality estimation (GMQE) scores [37] . DeepView Swiss-Pdb viewer v4.0 was used to perform pairwise L1 model comparisons by superimposition and predicted structural differences between models were measured in Å. The superimposition of L1 models was supported by a root mean square deviation (RMS) value that represents the average Å distance between corresponding atoms in the 2 models.
Statistical Analysis
Wilcoxon signed rank test was used to compare neutralization titers between HPV58 A1 and the other HPV58 variants. All tests were performed using, Stata 13.1 (StataCorp, College Station, TX).
RESULTS
HPV58 Amino Acid Variation and Pseudovirus Generation
The concatenated L2L1 (2.9 kb) DNA fragment contained sufficient numbers of diagnostic motifs to segregate variant sequences into the lineages and sublineages (A1, A2, A3, B1, B2, C, D1, and D2) previously defined [4, 8] by whole genome sequence analysis ( Figure 1B) . A consensus sequence for each sublineage was determined ( Figure 1C ) and codon-optimized HPV58 L1 and L2 genes representing these variants were generated ( Figure 1D ). HPV58 variant PsVs displayed similar particle dimensions (median 58 nm; IQR 56-59) and particle-to-infectivity ratios (median 8.6 × 10 2 ; IQR 4.5 × 10 2 -2.8 × 10 3 ).
Sensitivity of Variant HPV58 PsVs to Natural Infection Antibodies
Sera from women naturally infected with HPV were screened for neutralizing antibodies against HPV58 A1, A2, and C variant PsVs. Of 201 women with paired serum and DNA samples, 32 (16%) were positive for antibodies against at least 1 of these PsV. Of these individuals, partial LCR-E7 sequencing permitted HPV58 lineage or sublineage attribution in 21 cases (A2, 81%; A2/A3, 9.5%; B2, 4.8%; and C, 4.8%). Of the 32 antibody-positive women, 22 exhibited neutralization titers greater than 100. HPV58 lineage C PsV (median titer 25; IQR 25-25) exhibited a median 7.8-fold (IQR 5.0-15.7) reduction in neutralizing antibody titer compared to A1 (median titer 203; IQR 133-510) ( Figure 2A ). As censoring negative titers against HPV58 C would exaggerate this difference, it is prudent here to indicate that the median fold reduction neutralizing antibody titer without such censoring was 4.1 (IQR 2.5-8.7). HPV58 sublineages demonstrated similar (A3, D1, and D2), slightly higher (A2, B1), or lower (B2) sensitivity compared to A1. Anecdotally, 1 individual who was DNA positive for HPV58 C had a low neutralizing antibody titer (98) against variant C and was negative (<50) against the other variants.
Variable residues in the DE (residues 118, 133, and 137), FG (residues 266, 270, 273, and 285), and HI (residues 352 and 357) loops and residues within helices 2-3 (α2-α3; residues 386, 394, and 396) of the L1 protein, and 4 residues (342, 377, 380, and 416) in the L2 protein, defined the difference between A1 and C variant pseudoviruses ( Figure 1C) .
To ascertain whether these differences in neutralization sensitivity were solely due to variant residues in the L1 protein, 2 chimeric PsV (L1A1/L2C and L1C/L2A1) were generated ( Figure 2B) . The chimeric PsVs were tested alongside the consensus A1 and C PsV ( Figure 2C ). Median (IQR) neutralizing antibody titers against the L1A1/L2C chimera and the consensus A1 PsV were similar at 202 (IQR 129-546) and 148 (IQR 111-460), respectively. Conversely, both the L1C/L2A1 chimera and lineage C PsV were negative for neutralizing antibodies with median titers of 25 . These data indicate that substitutions in the L1 sequence of HPV58 lineage C ( Figure 1C) were entirely responsible for the noted decreased antibody sensitivity and that there was little or no influence of the L2 protein in this respect.
We next generated a series of chimeric HPV58 C PsVs containing single, double, or triple loops (DE, FG, and/or HI) representing the HPV58 A1 sublineage ( Figure 2B ). The individual HPV58 A1 loops had little or no impact on the recovery of the neutralization sensitivity associated with sublineage A1, with the double-loop chimeras exhibiting only marginally improved sensitivity ( Figure 2D ). The substitution of all 3 (DE, FG, and HI) loops from the A1 sublineage into the lineage C backbone was necessary and sufficient to confer the neutralization phenotype of HPV58 A1 sublineage.
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Sensitivity of Variant HPV58 PsVs to Variant-Specific Antisera
Rabbit immune sera generated against HPV58 A1 L1 VLP exhibited a marked reduction in recognition of the HPV58 C PsV (mean log 10 titer 2.5; SD 0.2) compared to the HPV58 A1 PsV (mean log 10 titer 4.8; SD 0.4) ( Figure 3A) . The use of chimeric L1 and L2 PsV demonstrated the dependency of this response on the L1 protein and the lack of a discernible contribution from the L2 protein (data not shown).
The contribution of the DE, FG, and/or HI loops to the sensitivity of the A1 lineage variant to neutralization by rabbit sera raised against HPV58 A1 VLP was also examined. In slight contrast to the requirement of all 3 (DE, FG, and HI) loops for reconstitution of target domains sensitive to antibodies elicited during natural infection, the FG loop was essential for recovery of the HPV58 A1 neutralization phenotype with some contribution from DE and HI loop residues.
We next generated antisera in BALB/c mice to L1L2 VLP representing both HPV58 A1 ( Figure 3B ) and C ( Figure 3C ) variants to ascertain whether these differences in variant antigenicity were reciprocal in nature. Similar to the rabbit antisera, mouse antisera raised against HPV58 A1 neutralized all variants to the same extent apart from HPV58 C, which exhibited a >2 log 10 reduction in neutralization sensitivity. Conversely, antisera raised against HPV58 C demonstrated a neutralizing antibody preference for this variant and a median 1.3 log 10 reduction in titer against the remaining variants. No reactivity was seen against the bovine papillomavirus control PsV.
To complement the HPV58 C PsV containing DE, FG, and HI loops representing HPV58 A1 sequences (C_DEFGHI) we made the reciprocal chimera consisting of HPV58 A1 PsV with DE, FG, and HI loops representing HPV58 C sequences (A1_DEFGHI). Variant-specific neutralizing antibody activity was wholly directed against epitope(s) in the DE, FG, and HI loops for both the HPV58 A1 and HPV58 C variants ( Figure 3B and 3C) .
Sensitivity of Variant PsVs to HPV58 A1 Monoclonal Antibodies
Eighteen murine MAbs raised against HPV58 VLP were tested against HPV58 A1 PsV and 6 MAbs with an IC 80 of <1 µg/mL were selected for further study (data not shown). The median Bovine papillomavirus (BPV) was used as a control for the experiments using mouse sera (arrow represents a neutralization titer of <50). For the rabbit sera, data represent the mean (± SD) titer of individual serum titers. For the mouse sera, the left panels represent a single titer generated using a pool comprising serum from each animal within each HPV58 A1 or C variant immune group whilst the right panels represent the mean (± SD) titer of individual serum responses.
(IQR) IC 80 for these 6 MAbs against HPV58 A1 was 0.008 (0.005-0.032) µg/mL which was similar to the majority of other variants except HPV58 C, for which the median IC 80 was 3.6 (IQR 3.0-4.1) log 10 higher (data not shown). These 6 MAbs were then tested against chimeric HPV58 C PsVs containing single, double, or triple loops (DE, FG, and/or HI) representing the HPV58 A1 sublineage (Figure 4) . Five MAbs had a requirement for residues within the DE loop (1D4, 11C7, 5G9, A13D9, and A14E5), with 3 having an additional contribution from residues within the FG and/or HI loops (5G9, A13D9, and A14E5). One MAb (9G4) exhibited a preferential requirement for residues in the FG loop, with some contribution from residues within the DE and HI loops.
HPV58 L1 Capsid Topography
We next used the crystal structure of the HPV58 L1 pentamer to model the locations of the variant residues between HPV58 A1 and C ( Figure 5A and 5B). Variant residues within the DE, FG, and HI loops did not form a single cluster of adjacent residues. Instead, variant residues in these loops resembled a T junction, whereby residues in the FG loop (A270 and V285) and DE loop (P137 and S133) form the main body and 2 distinct patches of residues (FG D273 and HI G352; FG K266 and HI D357) form the opposing arms. A homology model of HPV58 C was made and a pairwise comparison with HPV58 A1 was performed by superimposition and alignment of the alpha carbons (GMQE 0.99; QMEAN −1.41; RMS 0.1 Å). There was no apparent structural deviation of HPV58 C from A1 (<0.1 Å) ( Figure 5C ). Use of the HPV16 pentamer crystal structure (PDB accession 2R5H) as a template was rejected due to significant (4-5 Å) deviations between the HPV58 A1 homology model derived from the HPV16 pentamer and the actual HPV58 A1 pentamer crystal.
DISCUSSION
Estimates of the global dispersal and the historical origin of HPV58 lineage and sublineage variants have improved greatly with the use of whole-genome sequencing [38] . This study evaluated the potential consequences of naturally occurring polymorphisms within the HPV58 L1 and L2 genes attributed to these lineage and sublineage variants for capsid antigenicity. We generated L1L2 PsVs representing lineage and sublineage variants A1, A2, A3, B1, B2, C, D1, and D2 and evaluated their susceptibility to neutralization by HPV58-specific antibodies. There were some minor but nonetheless significant differences in sensitivity to neutralization by antibodies elicited following natural infection between sublineages A2, B1, and B2 and the reference A1 sublineage. Lineage C, however, exhibited markedly reduced sensitivity to antibodies elicited by natural infection. Where data were available, sublineage A2 was found to be the majority variant within the subset of HPV58 antibody-positive individuals. All PsVs were similarly sensitive to animal antisera raised against HPV58 A1 VLP, except lineage C, which demonstrated >2 log 10 reduced sensitivity. Conversely, antisera raised against HPV58 C demonstrated preferential reactivity against HPV58 C and markedly reduced sensitivity against the other variants. The lineage C PsV was essentially resistant to neutralization by murine MAbs raised against the HPV58 A1 L1 VLP.
Neutralizing antibodies generated during natural infection exhibited different specificities to those elicited by L1 VLP immunization, marked by differential dependency on the DE, FG, and HI loops. Antibodies elicited following natural infection had a requirement for antigenic domains encompassing variant residues from all 3 loops. Rabbit antisera appeared to have a slightly different requirement such that variant residues in the FG appeared to be essential, with support required from residues within either the DE or HI loops. Murine MAbs exhibited varied requirements, such that for some MAbs replacing variant residues in the HPV58 C DE loop with those from the A1 DE loop was necessary and sufficient to restore neutralization sensitivity, whereas for other MAbs a dependency on FG and/or HI loop resides was apparent.
Superimposition of an HPV58 C homology model onto the HPV58 A1 pentamer crystal demonstrated no structural difference overall. These data suggest that differences in neutralization sensitivity between A1 and C variants were likely due to alteration of a specific antibody epitope(s) rather than profound structural deviation induced by residue substitution.
There are few reports of MAbs being raised against HPV58 L1 [39] [40] [41] . One recent study examining the antigenicity of HPV58 at atomic resolution highlighted the dependency of one MAb on residues in neighboring DE loops with a contribution from the FG loop of one of the monomers [29] . The majority of the MAbs examined here also exhibited a DE loop dependency, whereby neutralizing activity was rescued by substitution of HPV58 A1 DE variant sequence substitutions into an HPV58 C background. The residues concerned (S133 and P137) are within a cluster of residues (particularly R135 [R161] and Q139 [Q165]) identified by crystallization of a Fab immune complex of the HPV58 pentamer [29] .
Near-atomic resolution by cryoelectron microscopy has greatly improved our understanding of the epitope footprints of a number of HPV16 MAbs [15, 42, 43] . The epitope of the type-specific neutralizing H16.V5 MAb, for example, includes loops from 2 neighboring L1 monomers with the majority of contact residues predicted to be in the DE and FG loops and a small contribution from residues located in the EF and HI loops. It is noteworthy that several positions within the HPV58 FG (K266, A270, and V285) and HI (D357) loops are equivalent to, or adjacent to, those in HPV16 that form part of the predicted H16.V5 epitope. In addition, HPV58 variant residues in the DE (S133), FG (K266 and D273), and HI (G352) can be found in equivalent positions in HPV31 [25] , HPV33 [26] , or HPV45 [27] and have an impact on the neutralization sensitivity of the genotype in question. Taken together these data suggest the presence of common domains between genotypes whose specific residues bestow genotype-specific antigenicity.
There are some limitations to this work. The number of samples representing HPV58 natural infection was relatively low, in part due to the low prevalence of HPV58, and primarily represented infections with the HPV58 sublineage A2. A larger study would be required to evaluate the extent of interlineage specific immune responses. However, the reciprocal immunogenicity profiles of HPV58 A1 and C suggest that antibodies elicited in individuals infected with HPV58 lineage C variants would likely demonstrate reduced recognition of other HPV58 variants. The use of chimeric antigens for epitope mapping necessarily evaluates only residues that differ between 2 or more variants and thus cannot speculate on the involvement of residues that are identical between the variants but nevertheless form part of the antibody footprint. The use of chimeric antigens is, however, a well-established technique to identify the contribution of variant residues to the phenotype of a target antigen [44, 45] . HPV PsVs have been used widely to monitor antibody responses to vaccines and natural infection [34, [46] [47] [48] , as well as elucidate steps in the entry process [49] . Nevertheless, differences between how PsVs behave in vitro and how authentic HPV58 lineage variants behave in vivo are uncertain, which is a limitation of all PsV-based systems.
These data inform our understanding of the antigenicity of the HPV58 structural proteins. For example, seroepidemiology studies using HPV58 A1-based antigens may underrepresent prior HPV58 infection in the population, particular for studies based in Africa where lineage C prevalence appears to be high. Similarly, antibodies elicited to the HPV58 antigen within the nonavalent vaccine may exhibit reduced effectiveness in populations with a high prevalence of HPV58 lineage C variants; however, it should be noted that data from a major nonavalent vaccine trial carried out in the Americas, Europe, and Asia demonstrated >95% vaccine efficacy against this genotype [50] . Nevertheless, further study will be required to ascertain whether the observed differential in vitro neutralization sensitivities will influence HPV vaccine impact modeling and postvaccine surveillance.
Notes
